Stoke Therapeutics, Inc. (STOK)
30.05
+0.24
(+0.81%)
USD |
NASDAQ |
Sep 08, 16:00
29.95
-0.10
(-0.33%)
Pre-Market: 09:15
Stoke Therapeutics Net Income (Quarterly) : -61.62M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -61.62M |
| March 31, 2026 | -50.00M |
| December 31, 2025 | -57.93M |
| September 30, 2025 | -38.35M |
| June 30, 2025 | -23.48M |
| March 31, 2025 | 112.88M |
| December 31, 2024 | -10.48M |
| September 30, 2024 | -26.43M |
| June 30, 2024 | -25.70M |
| March 31, 2024 | -26.37M |
| December 31, 2023 | -26.96M |
| September 30, 2023 | -24.54M |
| June 30, 2023 | -30.65M |
| March 31, 2023 | -22.54M |
| December 31, 2022 | -25.66M |
| September 30, 2022 | -26.11M |
| June 30, 2022 | -24.65M |
| Date | Value |
|---|---|
| March 31, 2022 | -24.65M |
| December 31, 2021 | -24.45M |
| September 30, 2021 | -22.60M |
| June 30, 2021 | -21.97M |
| March 31, 2021 | -16.79M |
| December 31, 2020 | -14.56M |
| September 30, 2020 | -13.68M |
| June 30, 2020 | -12.96M |
| March 31, 2020 | -11.04M |
| December 31, 2019 | -10.16M |
| September 30, 2019 | -8.604M |
| June 30, 2019 | -7.819M |
| March 31, 2019 | -5.742M |
| December 31, 2018 | -4.282M |
| September 30, 2018 | -3.317M |
| June 30, 2018 | -3.01M |
| March 31, 2018 | -1.912M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Biogen, Inc. | 97.50M |
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 9.325M |
| Total Expenses (Quarterly) | 70.94M |
| EPS Diluted (Quarterly) | -0.9334 |
| Enterprise Value | 1.585B |
| Gross Profit Margin (Quarterly) | 87.80% |
| Profit Margin (Quarterly) | -660.8% |
| Earnings Yield | -11.22% |
| Normalized Earnings Yield | -11.22 |